Altogether, our results define DYRK1A as an important therapeutic target for both colon cancer and triple negative breast cancer and highlight DYRK1A pharmacological inhibition as a potential new therapeutic approach for these cancer patients. This evidence concerns the gene DYRK1A and colonic neoplasm.